Ask about Retatrutide
Get a grounded answer across clinical evidence, community patterns, and risks.
Retatrutide
Also known as: LY3437943
GLP-1/GIP/Glucagon triple receptor agonist
Mechanism of Action
Activates GLP-1, GIP, and glucagon receptors. The glucagon component may enhance energy expenditure and fat oxidation beyond dual agonists.
Retatrutide (LY3437943) achieved up to 24.2% body weight reduction in 48 weeks in clinical trials — among the highest reported for any incretin-class compound. Currently in Phase 3 trials, it is the only investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The added glucagon activity may enhance energy expenditure and fat oxidation beyond dual agonists.
Reported Outcomes
Clinical grade reflects published research; Community grade reflects user reports (n=18,759).
Reduction in body weight
Retatrutide demonstrates profound efficacy in weight management, achieving up to 24.2% body weight reduction in 48 weeks. Meta-analyses consistently rank it as superior or highly potent compared to other incretins, with significant dose-dependent reductions in body mass index and waist circumference.
Reduced hunger and food cravings
Clinical trials indicate significant reductions in overall appetite, hunger, and prospective food consumption, particularly at doses equal to or greater than 4 mg. Improvements in eating behaviors, such as reduced disinhibition and perceived hunger, correlate significantly with weight loss outcomes.
Effects on sleep quality
Changes in muscle vs fat ratio
Treatment leads to substantial reductions in waist circumference and abdominal fat. While fat loss is significant, there is a noted reduction in lean mass, which is common with potent incretin therapies, necessitating attention to muscle preservation.
Changes in energy and fatigue levels
Effects on mood and cognitive function
Improved glycemic control and insulin sensitivity
Retatrutide significantly lowers fasting plasma glucose and HbA1c levels in patients with obesity and type 2 diabetes. Meta-analyses show it is highly effective at glycemic control, though some comparisons suggest tirzepatide may have a slight edge in this specific metric.
Effects on heart health markers
The peptide significantly reduces systolic and diastolic blood pressure and improves lipid profiles, including reductions in triglycerides and LDL cholesterol. These effects contribute to an overall reduction in cardiometabolic risk factors.
Who Discusses Retatrutide
From community reports with demographic data.
Gender
n=591
Age Distribution (limited data)
n=231
Side Effects
Based on 923 user reports (n=923). Frequency indicates how often each was mentioned.
Common (>5%)
Uncommon (1-5%)
Risks & Warnings
Important safety considerations based on clinical data and community reports.
Pancreatitis
Rare but serious. Stop medication and seek care for severe persistent abdominal pain.
Thyroid Concerns
GLP-1 agonists carry a boxed warning for thyroid C-cell tumors in rodents. Contraindicated in MEN2 or personal/family history of MTC.
Gallbladder Issues
Rapid weight loss increases gallstone risk. Report severe abdominal pain to healthcare provider.
Hypoglycemia Risk
Risk increases when combined with insulin or sulfonylureas. Monitor blood sugar carefully.
Muscle Loss
Rapid weight loss may include muscle. Adequate protein intake and resistance training recommended.
Psychiatric Effects
Monitor for mood changes. Report any concerning psychiatric symptoms to healthcare provider.
Hair Loss
May occur with rapid weight loss. Usually temporary (telogen effluvium). Ensure adequate nutrition.
Gastrointestinal Issues
GI side effects are the most commonly reported. Usually improve over time with slow titration.
Injection Site Reactions
Local reactions are common and usually mild. Rotate injection sites.
Dosing
Standard Protocol
- Starting Dose
- 1-2mg weekly (research protocols)
- Titration
- Titrate slowly over 4-8 weeks based on tolerance
- Half-life
- ~6 days (estimated)
- Administration
- Subcutaneous injection, once weekly
Community Dosing Patterns
Based on 1777 mentions
Community-reported patterns, not medical advice.
Pricing
Research-grade reference pricing for 10mg vial. Prices vary by vendor and quantity. Research chemicals require self-mixing and lack medical oversight. Shipping is not included.
We do not list vendors. Prices are aggregated from community reports and should be treated as rough ranges.
US Research Grade
Single small vial from US domestic vendors
US Research (Bulk)
Per-dose equivalent when buying larger US vials
China Research
Per-vial when buying 10-pack from Chinese vendors
Research
Key Studies
Nature Medicine (2024)
Front Neurosci (2023)
Endocrinol Metab (Seoul) (2024)
Gastroenterol Rep (Oxf) (2024)
Can Fam Physician (2024)
Commonly Stacked With
From community members' documented stacks involving Retatrutide.
Switching Patterns
Based on 2401 discussions about switching to or from Retatrutide.
→ Switching FROM
Users who switched to Retatrutide
← Switching TO
Users who switched from Retatrutide